Therapies & Developments

The therapeutic landscape of amyloidosis has undergone a fundamental transformation. From a disease with purely supportive treatment options, amyloidosis has evolved into a field with highly specific, life-saving therapies. This transformation is based on three essential therapeutic approaches: TTR stabilization, TTR production inhibition, and revolutionary gene-editing technologies. The introduction of specific therapies has fundamentally changed the paradigm — diagnostic delay is now a missed treatment opportunity.

Tafamidis was the first approved specific drug for ATTR amyloidosis and has fundamentally changed the therapeutic paradigm. As a TTR stabilizer, tafamidis binds to the thyroxine binding site of the TTR tetramer and prevents its dissociation, which leads to pathological fibril formation.

The landmark ATTR-ACT study (441 patients) demonstrated a 33% reduction in all-cause mortality over 30 months. This means approximately 7–8 patients must be treated to prevent one death over 2.5 years. Additionally, a 32% reduction in hospitalization rate was observed. Despite these successes, significant residual mortality of approximately 30% remains, driving development of alternative approaches.

With EU approval of acoramidis in March 2025, an advanced TTR stabilizer technology is available. The mechanism of action differs from tafamidis by additionally promoting hydrogen bonds between adjacent TTR subunits.

The ATTRibute-CM study (632 patients, 30 months) showed significant reduction in a hierarchical composite endpoint of death, cardiovascular hospitalizations, NT-proBNP changes, and 6-minute walk test deterioration. Notably, study participants were also allowed to receive tafamidis, suggesting potential additive effects.

Vutrisiran represents a paradigmatic shift through direct silencing of TTR production in the liver. This small interfering RNA (siRNA) reduces TTR synthesis at the source, offering a mechanistically different approach to stabilizers.

The HELIOS-B study (655 patients, 3-year follow-up): Vutrisiran reduced the risk of death and cardiovascular events by 28% over 3.5 years, and by 33% in patients without concurrent tafamidis therapy.

The European Commission granted approval in June 2025 for AMVUTTRA® for ATTR amyloidosis with cardiomyopathy — making it the first and only RNAi therapeutic approved in the EU for both polyneuropathic and cardiac ATTR manifestations.

NTLA-2001 represents the most visionary approach in ATTR therapy through permanent genetic modification. This CRISPR-Cas9 technology targets permanent disruption of TTR gene expression in the liver.

Early clinical results are extraordinarily promising: In a Phase I study with 6 patients, NTLA-2001 demonstrated a mean TTR reduction of 87%, with a maximum reduction of 96% after 28 days. This dramatic reduction far exceeds the effects of conventional therapies.

The FDA has granted NTLA-2001 Orphan Drug Status, and the technology is in the Phase III MAGNITUDE study for ATTR cardiomyopathy (completion expected April 2028). The potential of a single treatment with lasting effect could revolutionize amyloidosis therapy.

ALXN2220 from Alexion represents an innovative approach through direct binding and clearance of existing amyloid deposits. This monoclonal antibody is in the Phase III DepleTTR-CM study and received Fast Track status from the FDA in September 2024. The therapy could be particularly valuable for patients with advanced disease, as it can dissolve already-formed fibrils — a fundamentally different mechanism from all other approaches.

AL amyloidosis requires fundamentally different therapeutic approaches targeting the underlying plasma cell dyscrasia. The pipeline includes more than 10 different drugs in various development phases, including CAR-T cell therapies and bispecific antibodies for relapsed/refractory cases.

SGLT2 Inhibitors: New evidence shows that SGLT2 inhibitors — originally developed for diabetes — also reduce hospitalization risk in cardiac ATTR amyloidosis, establishing them as an important supportive therapy.

Combination Approaches: Current analyses show that the combination of aortic valve replacement and specific amyloidosis therapy with tafamidis in patients with combined aortic stenosis and ATTR amyloidosis offers optimal survival benefits — patients with both therapies showed long-term survival similar to those with isolated aortic stenosis without amyloidosis.

The next years will likely bring further expansion of therapeutic options:

The regulatory landscape has dramatically improved: FDA and EMA have established expedited pathways for orphan drugs, accelerating development and approval. The challenge ahead is optimizing patient selection, developing biomarkers for therapy monitoring, and managing the costs of high-price orphan drug therapies.